© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA
Articles
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN Trial
July 16, 2020
The trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on the Phase 3 ASPEN Trial
June 23, 2020
Results from the trial indicated that zanubrutinib was associated with a higher complete response or very good partial response rate and demonstrated clinically meaningful advances in safety and tolerability in patients with Waldenström macroglobulinemia.
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial
June 08, 2020
The trial compared zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.